Pre-Open Stock Movers:

Liminal BioSciences Inc. (Nasdaq: LMNL) 47% HIGHER; announced today that the U.S. Food & Drug Administration (FDA) has approved Ryplazim for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics Inc., holder of the biological license application ("BLA") for Ryplazim®. With this approval, Ryplazim® becomes the first FDA-approved therapy for this rare genetic disorder.

U.S. Concrete, Inc. (NASDAQ: USCR) 28.7% HIGHER; Vulcan Materials Company (NYSE: VMC), a leading producer of construction aggregates, and U.S. Concrete, Inc. (NASDAQ: USCR), a leading supplier of aggregates and ready-mixed concrete, today announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Vulcan will acquire all of the issued and outstanding shares of U.S. Concrete common stock for a purchase price of $74.00 per share in cash, which represents a total equity value of $1.294 billion. The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in the second half of 2021, subject to U.S. Concrete shareholder approval, regulatory clearance, and other customary closing conditions.

QTS Realty Trust (NYSE: QTS) 22% HIGHER; QTS and Blackstone (NYSE: BX), today announced that they have entered into a definitive agreement under which Blackstone Infrastructure Partners, Blackstone Real Estate Income Trust, Inc. and other long-term perpetual capital vehicles managed by Blackstone will acquire all outstanding shares of common stock of QTS Realty Trust for $78.00 per share in an all-cash transaction valued at approximately $10 billion1, including the assumption of debt. The purchase price represents a premium of 21% to QTS' closing share price as of June 4, 2021 and a 24% premium to the volume weighted average share price over the last 90 days. The transaction was unanimously approved by the QTS Board of Directors and is expected to close in the second half of 2021.

MoSys, Inc. (NASDAQ: MOSY) 16.9% LOWER; entered into a definitive agreement with institutional investors for the purchase and sale of 1,818,181 shares of its common stock at a price of $7.15 per share for gross proceeds of approximately $13 million in a registered direct offering priced at-the-market under Nasdaq rules. MoSys intends to use the proceeds for working capital and general corporate purposes. The offering is expected to close on or about June 9, 2021, subject to the satisfaction of customary closing conditions.

ChromaDex Corp. (NASDAQ: CDXC) 12% HIGHER; announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across the United States. Walmart is the first major U.S. retailer to bring this well-studied healthy aging nutrient to stores.

Macquarie Infrastructure Corporation (NYSE: MIC) 10% HIGHER; MIC and KKR today announced the signing of a definitive agreement for MIC to sell its Atlantic Aviation business to KKR for $4.475 billion in cash and assumed debt and reorganization obligations. Atlantic Aviation operates one of the largest networks of fixed base operations (FBOs) in the U.S. providing a full suite of critical services to the private aviation sector.

MoneyGram International, Inc. (NASDAQ: MGI) 9.3% LOWER; announced today that it has established an "at-the-market" equity offering program under which it may offer and sell, from time to time, shares of its common stock having an aggregate sales price of up to $100 million, and has entered into an ATM Equity OfferingSM Sales Agreement with BofA Securities, Inc. ("BofA"), as sales agent.

bluebird bio, Inc. (Nasdaq: BLUE) 7.4% HIGHER; today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy (beti-cel; licensed as ZYNTEGLO in the EU and the UK) for adult, adolescent and pediatric patients with transfusion-dependent -thalassemia (TDT). The company is working closely with study investigators and clinical trial sites to resume all study activities as soon as possible.

G-III Apparel Group (NASDAQ: GIII) 7.3% HIGHER; reported Q1 EPS of $0.53, $0.38 better than the analyst estimate of $0.15. Revenue for the quarter came in at $519.9 million versus the consensus estimate of $462.03 million. G-III Apparel Group sees FY2022 EPS of $2.60-$2.70, versus the consensus of $2.41. G-III Apparel Group sees FY2022 revenue of $2.57 billion, versus the consensus of $2.53 billion.

AMC (NYSE: AMC) 4.6% HIGHER; sees continued upside momentum on WSB/Reddit trade

Tellurian (NASDAQ: TELL) 4.3% HIGHER; Morgan Stanley upgraded from Underweight to Equalweight with a price target of $8.00 (from $2.00).

Biogen Inc. (NASDAQ: BIIB) 3.4% HIGHER; FDA set to rule on controversial Biogen Alzheimer's drug.

Magnite (NASDAQ: MGNI) 2.5% HIGHER; Truist Securities upgraded from Hold to Buy with a price target of $37.00.

Peloton Interactive (NASDAQ: PTON) 2% HIGHER; Loop Capital initiates coverage with a Buy rating and a price target of $140.00.

You May Also Be Interested In

• Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
• 23andMe (ME) stock jumps as CEO plans to take company private
• DermTech (DMTK) to Explore Strategic Alternatives and Implement Restructuring Plan